Hydrogel-load exosomes derived from dendritic cells improve cardiac function via Treg cells and the polarization of macrophages following myocardial infarction

Youming Zhang²†, Zichun Cai³†, Yunli Shen²†, Qizheng Lu², Wei Gao⁴, Xin Zhong⁴, Kang Yao⁴, Jie Yuan⁴* and Haibo Liu¹*

Abstract

Background: Myocardial infarction (MI) is one of the leading causes of global death. Dendritic cell-derived exosomes (DEXs) provide us with the possibility of improving cardiac function after MI but are limited by low retention times and short-lived therapeutic effects. In this study, we developed a novel drug delivery system incorporating alginate hydrogel that continuously releases DEXs and investigated the mechanisms underlying the action of DEXs in the improvement of cardiac function after MI.

Results: We incorporated DEXs with alginate hydrogel (DEXs-Gel) and investigated controlled released ability and rheology, and found that DEXs-Gel release DEXs in a sustainable manner and prolonged the retention time of DEXs but had no detrimental effects on the migration in vivo. Then DEXs-Gel was applied in the MI model mice, we found that DEXs-Gel significantly enhanced the therapeutic effects of DEXs with regards to improving cardiac function after MI. Flow cytometry and immunofluorescence staining revealed that DEXs significantly upregulated the infiltration of Treg cells and M2 macrophages into the border zoom after MI, and DEXs activated regulatory T (Treg) cells and shifted macrophages to reparative M2 macrophages, both in vitro and in vivo.

Conclusion: Our novel delivery method provides an innovative tool for enhancing the therapeutic effects of DEXs after MI. Further analysis revealed that DEXs exert effect by activating Treg cells and by modifying the polarization of macrophages.

Keywords: Myocardial infarction, Dendritic cell, Exosomes, Alginate hydrogel, Regulatory T cells, Macrophage

© The Author(s) 2021, corrected publication 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
**Introduction**

Worldwide, myocardial infarction (MI) is still the primary cause of cardiovascular mortality and disability [1]. The development of clinical treatments, particularly percutaneous coronary intervention and coronary artery bypass grafting, has helped to reduce the mortality associated with MI; however, we do not yet possess the ability to repair and reconstruct damaged myocardium [2]. The progression of MI often leads to adverse ventricular remodeling, including late myocardial fibrosis and irreversible ventricular dilatation; ultimately, these conditions may eventually cause heart failure and death [3, 4].

The immune system plays a central role in both the inflammatory phase and reparative phase after MI [5, 6]; both immune cells and secreted exosomes are known to take part in the reparative phase and act via a paracrine mechanism. Exosomes (EXs) are a type of extracellular vesicle that are secreted by cells and contain proteins, DNA, and RNA [7]. Over recent years, it has become increasingly clear that exosomes from various cell types engage with the immune system as messengers of intercellular communication [7–9]. Dendritic cell (DC)-derived exosomes (DEXs) are known to participate in antigen presentation [10], immune activation, and inhibition [11]. In a previous study we found that DEXs could improve cardiac function via CD4+ T cells [12]. However, we, and other researchers [13, 14], also found that the intravenous administration of EXs was associated with a short half-life due to clearance by mononuclear phagocytes and accumulation in the liver and spleen; furthermore, the therapeutic effect was significantly limited by low retention rates. However, the simple delivery of a greater number of EXs did not prolong retention times; rather, this generated a range of additional problems [15]. Therefore, there is a clear need to develop a new approach to improve the retention time of DEXs.

Alginate hydrogel (gel) has been widely applied in the fields of tissue engineering and regenerative medicine due to good biocompatibility, the fact that the gelation process is mild, and because its mechanical properties are similar to the extracellular matrix (ECM) [16]. Gel can also provide physical support and increase scar thickness in damaged myocardium when injected into the infarct area after MI [17]. However, whether alginate hydrogel could help to improve cardiac function after MI remains controversial [18–20]. In a recent study, Lü et al. used alginate hydrogel as a carrier for bioactive substances. These authors injected a gel that was loaded with bone marrow mesenchymal stem cell (MSC)-derived small extracellular vesicles (sEVs) into the MI infarct area and found that the gel could prolong the retention of sEVs and enhance the therapeutic effect of sEVs with regards to cardiac function after MI [20]. Thus, we hypothesized that DEXs loaded in gel (DEXs-Gel) might create an efficient drug delivery system to prolong the retention of DEXs. In a previous study, we demonstrated that DEXs improved cardiac function by migrating into the lymphatic system (such as the spleen or lymph nodes) and by activating CD4+ T cells [12]; however, whether the gel affects the migration of DEXs and whether DEXs-Gel could enhance the therapeutic effects of DEXs remain unknown.

Regulatory T (Treg) cells are a subset of CD4+ T cells and play a dominant role in the control of self-reactive T cells and the maintenance of immunological self-tolerance [21]. An exaggerated or persistent inflammatory activation after MI leads to maladaptive healing and subsequent remodeling of the left ventricle [22]. Recent studies also showed that Treg cells play a beneficial role in wound healing after MI by modulating the differentiation of monocytes and macrophages [22, 23]. In addition, Choo et al. [24], showed that the administration of MI mice with dendritic cells (DCs) primed with infarct lysate, or the serum of mice with MI, induced the systemic activation of Treg cells, thus eliciting an earlier macrophage subset shift from inflammatory M1 to reparative M2 macrophages. These alterations in the immune environment within the infarcted heart resulted in better wound remodeling, preserved left ventricle (LV) systolic function after myocardial tissue damage, and improved survival [24]. DEXs contains substances secreted from DCs that may act as intercellular messengers for immune cells [7–9]; they may also participate in antigen presentation [10], immune activation and inhibition [11] as DCs. It is also possible that DEXs could activate Treg cells and lead to an earlier shift in the macrophage subset from inflammatory M1 to reparative M2 macrophages as DCs.

In this study, we developed an injectable alginate-based composite DEXs-Gel in an attempt to enhance the in vivo retention of DEXs and improve its therapeutic effects after MI. We also investigated whether DEXs-Gel could sustainably release DEXs in vitro and used a small animal fluorescence imaging system to compare the retention and migration of DEXs in vivo between the injection of DEXs-Gel and DEXs alone. We also compared the two experimental groups with regards to cardiac function, angiogenesis, myocardium apoptosis, and immune cell activation. Finally, we explored the mechanisms underlying the beneficial effects of DEXs on cardiac function after MI and the superiority of DEXs-Gel in the treatment of MI.

**Materials and methods**

**Animals**

Wild-type mice (C57BL/6; all males) were purchased from the Shanghai Laboratory Animal Center, China.
Male, 6-week-old C57BL/6 mice, weighing 16–20 g, were used for the culture of bone marrow-dendritic cells (BMDCs) and bone marrow-derived macrophages (BMDMs). In addition, 8-week-old male C57BL/6 mice, weighing 22–28 g, were used to construct the MI models and were subjected to different injections. All mice were housed under pathogen-free conditions in a standard laboratory with a controlled room temperature of 22 ± 1 °C, a humidity of 65–70%, and a 12:12-h light-dark cycle, with free access to food and water. Animal care and treatment complied with the standards approved by the Institutional Review Board of Zhongshan Hospital of Fudan University and the Shanghai Institutes of Biological Sciences-CAS (Reference: A5894-01).

Cell isolation and culture
BMDCs were isolated from C57BL/6 mice and cultured with a non-serum medium to eliminate the interference of exosomes caused by fetal bovine serum (FBS), as described previously [12]. In brief, the mice were sacrificed by cervical dislocation and the femurs were isolated. The bone marrow cells were then washed out from the femurs and cultured in Roswell Park Memorial Institute (RPMI) 1640 (Gibco, USA) supplemented with 10% FBS, Life Technologies, USA) and 1% Penicillin/Streptomycin (Gibco, USA) containing 10 ng/ml of granulocyte-macrophage colony-stimulating factor and 1 ng/ml of IL-4 (both from R&D Systems, USA). The medium was changed every other day. On day 7, the BMDCs were collected and treated with the supernatants of necrotic HL-1 cells for 24 h and then cultured with a non-serum medium to eliminate the interfering effect of FBS on exosomes.

BMDMs were isolated from C57BL/6 mice, as described above. Then, cells were cultured in RPMI 1640 (Gibco, USA) supplemented with 10% FBS, Life Technologies, USA) and 1% Penicillin/Streptomycin (Gibco, USA) containing 10 ng/ml of macrophage colony-stimulating factor (R&D Systems, USA). The medium was changed every other day. On day 7, the BMDMs were collected and used for subsequent experiments.

HL-1 cells and mouse thymic regulatory T (Treg) cells were purchased from Bluebio (Shanghai) Biotechnology Development Co., Ltd and cultured in Dulbecco’s modified Eagle’s medium (DMEM, Gibco) supplemented with 10% FBS (Life Technologies, USA) and 1% Penicillin/Streptomycin (Gibco, USA).

All experiments were performed under sterile conditions and the cultures were maintained at 37 °C in 5% CO₂ and 95% humidity.

Simulation of the post-MI cardiomyocyte microenvironment in vitro
Three types of samples were used to mimic the MI microenvironment: (i) the supernatants of necrotic HL-1 cells; (ii) the supernatants of hypoxic primary cardiomyocytes; and (iii) the supernatants of infarcted mouse myocardium; the acquisition of these samples was described in our previous study [12]. Data from our previous study suggested that treatment with the supernatants of necrotic HL-1 cells or hypoxic primary cardiomyocytes in vitro activates DCs in mice in a similar manner to MI. In the present study, we used the supernatants of necrotic HL-1 cells to mimic the MI microenvironment. In brief, we collected 100 μl of supernatant from necrotic HL-1 cells. Next, we removed cell membrane particles by centrifugation at 1500g at room temperature for 30 min. The purified supernatant of HL-1 cells was then incubated with 1 × 10⁶ BMDCs for 24 h. All experiments were performed under sterile conditions.

Isolation and characterization of DEXs
In this study, we used the ExoQuick-Tc™ Exosome Precipitation Solution (System Biosciences Inc.) to isolate DEXs; this system was used in accordance with the manufacturer’s instructions. In brief, a 1/5 volume of ExoQuick-Tc™ Exosome Precipitation Solution was added to 10 ml of supernatant from the DCs and then refrigerated overnight at 4 °C. Then, the samples were centrifuged at 1500g at room temperature for 30 min and the supernatant was removed. DEXs were then re-suspended in 1 ml of PBS (Hyclone; Cytiva) and used for subsequent experiments. Western blotting was then used to identify surface makers on the DEXs, including CD63 (ab193349, Abcam, USA) and Alix (ab275377, Abcam, USA). An H7500 transmission electron microscope (Hitachi, Japan) was then used to determine particle morphology. The particle size distributions of isolated DEXs suspended in PBS was also determined using a Nanosight NS300 (Malvern, UK).

Cell experimental protocol
Macrophages were treated with 100 ng/ml of lipopolysaccharide (LPS, Sigma-Aldrich) or 10 ng/ml of IL-4 and IL-13 (PeproTech, USA) for 48 h and used as M1- or M2-positive controls. DEXs (40 μg/ml) or Treg cells (1 × 10⁶ cells/ml) were incubated with 2 × 10⁶ macrophages for 48 h and used as experimental groups. Untreated cells were used as negative controls. After 48 h of culture, we collected cells from each group for flow cytometry.
Flow cytometry analysis
Samples were incubated with an Fc receptor blocker (CD16/32, BD Bioscience) to reduce nonspecific antibody binding. Freshly isolated samples were resuspended in staining buffer (R&D Systems) and stained with F4/80-FITC (eBioscience) for 30 min at 4 °C. For intracellular staining, we used the Intracellular Fixation and Permeabilization Kit (BD Bioscience); this was used in accordance with the manufacturer’s instructions. Cells were then washed and stained with iNOS-APC (eBioscience) and CD206-PE (eBioscience). Flow cytometry was performed using a FACS Aria flow cytometer (BD Bioscience) and data were analyzed with FlowJo V10.6.2 software (TreeStar, Ashland, OR).

Incorporating DEXs with alginate hydrogel
We mixed 2% (wt/vol) sodium alginate and 1.5% (wt/vol) calcium alginate (both from Sigma) at a volume ratio of 1:1 to form the alginate hydrogel. DEXs (30 µg DEXs in 15 µl of gel) were then added into the alginate solution which was then stirred and mixed to form alginate hydrogel incorporating DEXs. A MARS60 (HAAKE, Germany) rheometer was used to evaluate rheological behavior. Finally, the samples were freeze dried and microstructure was observed with a Gemini 300 transmission electron microscope (ZEISS, Germany).

Assessing the release ability of DEXs-Gel
For release studies, 100 µl of alginate hydrogel incorporating 80 µg of DEXs were incubated in 200 µl of PBS (Hyclone; Cytiva) at 37 °C in a 5% CO2 atmosphere. The supernatant was removed and fresh PBS (Hyclone; Cytiva) was added every 2 days. The number of DEXs released into the medium was then determined by the Enhanced BCA Protein Assay Kit (P0010, Beyotime, Biotechnology, Shanghai, China).

Induction and treatment of a mouse model of MI
Coronary artery ligation was used to induce a mouse model of MI. In brief, mice were anesthetized by 2% isoflurane inhalation (RWD Life Science, China) with 2% isoflurane delivery system (Harvard Bioscience, Inc.) and then ventilated with a rodent ventilator (Harvard Bioscience, Inc.). A small incision was made on the skin of the left chest to allow us to dissect and retract the major and minor pectoral muscles. Next, we opened the chest, exposed the heart, and used 8–0 silk sutures to ligate the left coronary artery (LCA). Successful infarction was determined by observing the blanching of the myocardium in the affected area. Mice undergoing the same surgical procedure, but without LCA ligation, were used as a sham group. After successfully constructing the MI model, we injected 15 µl DEXs (30 µg DEXs in 15 µl PBS), Gel, or DEXs-Gel (containing 30 µg of DEXs), into the myocardium of the left ventricle at three sites (two sites at the border and one site at the infarct area). Finally, we evacuated remaining air, sutured the skin, placed the mice back to their cages, and waited for them to come round from the anesthesia.

DEXs labeling and fluorescence imaging
DEXs suspended in PBS (Hyclone; Cytiva) were labeled with a 1:400 dilution of DiR (Thermo Fisher Scientific) for 30 min at 37 °C. Excess dye was then removed and the DEXs purified using exosome spin columns (MW 3000; Thermo Fisher Scientific). Near-IR fluorescence images were then acquired using the IVIS Spectrum System (PerkinElmer). We used this system to compare the maximal fluorescence intensity of the body and main organs between the DEXs and DEXs-Gel groups.

Echocardiography
In vivo cardiac function was determined by echocardiography (Vevo 2100, VisualSonics, Toronto, Canada) on day 7 and day 14 post-surgery. Mice were anesthetized with 2% isoflurane (RWD Life Science, China) and oxygen, and two-dimensional echocardiographic views of the left ventricular long axis were obtained through the anterior and posterior LV walls at the level of the papillary muscle tips below the mitral valve. Then, we used Vevo 2100 workstation software to calculate the left ventricular ejection fraction (LVEF), left ventricular fractional shortening (LVFS), left ventricular end-diastolic diameter (LVIDD), and left ventricular end-systolic diameter (LVIDS). All echocardiograms were evaluated in a blinded manner.

Histology
Mice were sacrificed by cervical dislocation on day 28. Then, we used Masson’s trichrome staining to determine infarct size and the thickness of the wall in the infarct zone. In brief, heart samples were fixed with 4% paraformaldehyde at room temperature for 24–48 h. Then, we embedded samples of heart tissue in paraffin and prepared tissue sections (5 µm in thickness); these were then dewaxed in xylene (Sangon Biotech Co., Ltd.) and rehydrated using ethanol. Finally, sections were stained with Masson’s trichrome reagent and sealed with neutral gum. After observation with an optical microscope, the infarct area was calculated by the sum of the endocardial and epicardial length of the infarct zone divided by the total length of the endocardial and epicardial left ventricle. In addition, the thickness of the wall in the infarct area was averaged from three to five measurements of scar thickness using Image J V1.53e software.
Immunofluorescence staining
We also harvested samples of heart tissue for paraffin-embedding and sectioning on days 3, 5, and 14. The sections were dewaxed, rehydrated and antigen retrieval was performed by boiling the sections in 0.01 M citrate buffer (Sangon Biotech Co., Ltd. Shanghai, China). Then, the sections were incubated overnight at 4 °C with rabbit anti-iNOS (ab3523, Abcam, USA), rabbit anti-CD206 (ab64693, Abcam, USA), and rabbit anti-Foxp3 (ab75763, Abcam, USA). Rabbit anti-CD31 (GB11063, Servicebio Technology Co., Ltd. Wuhan, China) was used to investigate angiogenesis. Cardiac Troponin T Rabbit pAb (GB11364, Servicebio Technology Co., Ltd. Wuhan, China) was used to determine the extent of viable myocardium in the infarct area. Next, the sections were incubated with corresponding fluorescent dye-conjugated secondary antibodies (GB25303; GB21303, Servicebio Technology Co., Ltd. Wuhan, China) and nuclei were counterstained with DAPI (G1012, Servicebio Technology Co., Ltd. Wuhan, China) in accordance with the manufacturer’s instruction. We also used a TUNEL kit (G1501, Servicebio Technology Co., Ltd. Wuhan, China) to evaluate cell apoptosis. The relative proportions of cells that were positive for iNOS, CD206, Foxp3, and TUNEL, were then determined from the total number of cells; four hearts were evaluated per group. We also counted the number of CD31-positive blood vessels in four hearts per group. All evaluations were performed in the border zones and analyzed with Image J V1.53e software.

Statistical analysis
Results are shown as mean±standard deviation (SD). Statistical analyses of differences between two groups were performed using the unpaired t-test while differences between three or more groups were performed by one-way analysis of variance (ANOVA) followed by post-hoc Tukey’s multiple tests. Statistical tests were performed with Prism GraphPad Prism V8.0.1 Software (GraphPad Prism Software Inc.). p < 0.05 was considered to be statistically significant.

Results
Characterization of DCs and DEXs
We used the supernatants of necrotic HL-1 cells to mimic the MI microenvironment. Cultured BMDCs were either unstimulated (imDCs) or stimulated with the supernatants of necrotic HL-1 cells (tDCs), or LPS (mDCs), for 24 h and then analyzed by flow cytometry. Figure 1A shows that supernatants from necrotic HL-1 cells upregulated the expression of several markers of DC maturation (CD40, CD80, and CD86), as demonstrated in a previous study [24].

Next, we used the ExoQuick-Tc™ Exosome Precipitation Solution to isolate DEXs from the culture medium of DCs. The ultrastructure of the DEXs were demonstrated by transmission electron microscopy (TEM) (Fig. 1B) and particle size distributions were determined via nanoparticle tracking analysis (NTA); the mode diameter was 106.5 nm (Fig. 1D). We also used western blotting to demonstrate the expression of exosomal markers (CD63 and Alix; Fig. 1C).
Characterization of the Gel and DEXs-Gel

The Gel and DEXs-Gel (Fig. 2A) were both achromatous and existed in a non-liquid form. Next, we evaluated the injectability and viscosity of the hydrogel with a 29G needle (Fig. 2B). Next, the microstructure of the Gel and DEXs-Gel were captured by scanning electron microscopy (Fig. 2C). Then, the rheological properties of the Gel and DEXs-Gel were examined (Fig. 2E, F); we found that their storage modulus ($G'$) lay between 400 and 1800 Pa; this is considered to represent an appropriate $G'$ for cardiac tissue engineering [25]. Finally, we determined the controlled release ability of the DEXs-Gel (Fig. 2D); analysis showed that DEXs-Gel could release DEXs in a controlled manner for 10–12 days in vitro.

DEXs-Gel released DEXs in a sustainable manner and prolonged the retention of DEXs in vivo

Next, we determined the release ability of DEXs-Gel by using a BCA Protein Assay Kit to detect the DEXs that had been released into the medium. We found that DEXs-Gel could sustainably release DEXs in vitro (Fig. 2D). For in vivo studies, we labeled DEXs with DIR before incorporating them into alginate hydrogel; then, we injected DEXs alone, or DEXs-Gel, into the infarcted area in MI mice. On days 3, 7 and 14, we acquired near-IR fluorescence images from the body and main organs with a IVIS Spectrum System. The results (Fig. 3A and B) showed that there were fewer remaining DEXs in the DEXs injection group on day 7 compared with the DEXs-Gel injection group. By day 14, DEXs had been eliminated in the DEXs injection group; however, an abundance of DEXs had been retained by the DEXs-Gel injection group. These results indicated that alginate hydrogel prevented the clearance of DEXs and prolonged its retention in vivo. To investigate the distribution of DEXs in vivo, we evaluated fluorescent signals in the heart, lungs, livers, and lymph of each group (Fig. 2C–F). Although we injected DEXs into the heart, we found that they had migrated to the axillary lymph nodes in both groups by day 3. In the DEXs-Gel injection group, we observed DEXs in the inguinal lymph nodes on day 7. These results indicated that DEXs participated in antigen presentation as dendritic cells, as described previously [10]. However, we observed stronger fluorescent signals in the liver in the DEXs injection group when compared with the DEXs-Gel injection group on day 3. This indicated that more DEXs had been eliminated in the DEXs injection group; the liver is the main organ responsible for the elimination of DEXs [13, 14]. On day 7, few DEXs had been retained in the hearts or lymph
nodes of mice in the DEXs injection group; almost all fluorescent signals were in the liver. This information suggested that the majority of the DEXs were not functional in vivo, however, although an abundance of DEXs were observed in the heart and lymph nodes in the DEXs-Gel injection group. On day 14, the DEXs in the DEXs-Gel injection group had entered the clearance stage but had been cleared completely in the DEXs injection group.

**DEXs-Gel enhanced cardiac function after MI**
We performed echocardiography on days 7, 14 and 28 after surgery. Figure 4A–E show that the DEXs had
Fig. 4 DEXs-Gel enhanced cardiac function after MI. 

A Representative images of echocardiography in different groups.

B–E Analysis of left ventricular ejection fraction (LVEF), left ventricular fraction shortening (LVFS), left ventricular end diastolic diameter (LVIDd), and left ventricular end systolic diameter (LVIDs). n = 5, *p < 0.05, **p < 0.01, ***p < 0.001
demonstrated their therapeutic effect by improving cardiac function on day 7; however, the Gel injection did not show any obvious effects with regards to the recovery of cardiac function in mice on day 7, as described previously [18, 19]. However, on day 14, the cardiac function of the MI group was worse than on day 7; mice in the and Gel injection group had maintained their cardiac function and showed distinct advantages compared with the MI group. Of all groups, mice in the DEXs-Gel injection group exhibited the best performance in terms of improved cardiac function, demonstrating almost the same effect as that in the DEXs injection group on day 7, but with significant improvement on day 14. On day 28, the cardiac function of mice in the MI group had become slightly better than on day 14. Mice in the Gel group maintained a similar level of cardiac function as on day 14, thus indicating that Gel injection did not improve cardiac function but could prevent cardiac function from becoming worse. Mice in the DEXs and DEXs-Gel group improved cardiac function; mice in the DEXs-Gel showed better effects than mice in the DEXs group. These results indicated that DEXs-Gel not only prolonged the retention time of DEXs but also improved the therapeutic effect.

**DEXs regulated inflammation via Treg cells and M2 macrophage infiltration**

Although the inflammatory cascade plays an important role in the response to cardiac injury, excessive inflammatory reactions are not conducive to heart repair. Evidence from two recent trials showed that the anti-inflammatory effects of colchicine reduced the risk of cardiovascular events in patients with recent myocardial infarction [26, 27]. A study on MI mice models also found that although heart function is enhanced by stem cell therapy after MI, it was not associated with the production of new cardiomyocytes; rather, the enhancement was associated with an acute sterile immune response characterized by macrophages [28]. Collectively, these results emphasized the vital effects of anti-inflammatory therapy after MI. We investigated the therapeutic effect of DEXs and DEXs-Gel in terms of improvements in cardiac function; however, the precise mechanisms involved has yet to be elucidated. Therefore, we detected the immunoregulation status in each group of mice. Considering that pro-inflammatory cells peak on day 3 after MI and anti-inflammatory cells peak on days 5–7 [2, 29], we chose day 5 after surgery to detect immune cell infiltration by immunofluorescence staining. We found that the injection of DEXs reduced the infiltration of iNOS+ M1 pro-inflammatory macrophages and increased the infiltration of CD206+ M2 anti-inflammatory macrophages and Foxp3+ Treg cells into the border zone (Fig. 5A–H). These results confirmed our hypothesis that DEXs could activate Treg cells, thus leading to an earlier shift in the macrophage subset from inflammatory M1 to reparative M2 macrophages as DCs.

**DEXs regulated the polarization of macrophages via Treg cells**

We previously found that DEXs activated Treg cells and regulated the polarization of macrophages after MI, although the specific mechanism involved remained unknown. To solve this problem, we co-cultured DEXs, macrophages, and Treg cells, in vitro and determined the ratio of M1/M2 macrophages by flow cytometry. We found that Treg cells could shift macrophages to become M2-like type cells rather than M1-like type cells; however, DEXs stimulated macrophages to express both M1 and M2-like type cells with a greater tendency for the M1-like type than the M2-like type (Fig. 6A–E). Considering that the immunofluorescence staining results showed a significant infiltration of Treg cells and M2 macrophages into the border zone after the injection of DEXs or DEXs-Gel, we hypothesized that DEXs regulate M1/M2 macrophage polarization via Treg cells and not by themselves. Furthermore, near-IR fluorescence images also confirmed that DEXs had migrated into lymph nodes after intramyocardial injection. Thus, we concluded that DEXs had migrated into the lymph nodes and activated Treg cells to regulate the shift of macrophages towards M2-like type cells after intramyocardial injection and thus improved cardiac function post-MI.

**DEXs protected cardiac cells against apoptosis and promoted angiogenesis**

Ischemia and hypoxia, generated by the blocked blood supply to the heart after MI, inevitably results in damage to the cardiac cells. The regeneration of blood vessels is important if we are to rescue ischemic myocardium and avoid the apoptosis of cardiac cells. Therefore, we compared cardiac cell apoptosis via TUNEL staining on day 3
Fig. 5 (See legend on previous page.)
and angiogenesis via CD31 staining on day 14. We found that the proportion of apoptosis cells in the border zoom were markedly lower in the DEXs and DEXs-Gel injection group when compared with the MI and Gel injection group (Fig. 7A and B). Furthermore, we observed new vessels that stained positive for CD31 (Fig. 7C and D) in the DEXs and DEXs-Gel injection group. Furthermore, the DEXs-Gel injection group exhibited the best ability to promote angiogenesis when compared to the other groups. Collectively, these results indicated that DEXs can protect cardiac cells against apoptosis and promote angiogenesis. Data also indicated that DEXs-Gel prolonged the therapeutic effects of DEXs therapeutic effects but did not enhance these effects directly.

### DEXs-Gel increased the thickness of the infarct wall and reduced infarct size

We confirmed that DEXs-Gel could enhance cardiac function via immunoregulation, anti-apoptosis, and by promoting angiogenesis. Next, we investigated these processes by histological analysis. For each group, we performed Masson's trichrome staining on day 28 after...
surgery. We found that Gel injection provided physical support and increased the scar thickness in damaged myocardium when injected into the infarcted area after MI (Fig. 8A–C), as previously described [17]. Furthermore, the injection of DEXs reduced the infarct size and rescued more damaged myocardium when compared to the MI and Gel group. DEXs-Gel injection yielded two beneficial effects related to DEXs while Gel injection resulted in better cardiac function improvement when compared to the other groups. These results indicated
that DEXs-Gel not only prolonged the retention time of DEXs; they also provided more physical support than DEXs injection and thus enhanced cardiac function after MI, thus suggesting that DEXs-Gel is a better approach for the treatment of MI.

**Discussion**

In this study, we demonstrated that DEXs significantly upregulated the infiltration of Treg cells and M2 macrophages into the border zoom after MI, thus indicating that DEXs improved cardiac function via these two types of cells. Furthermore, we performed flow cytometry to identify the specific relationships among DEXs, Treg cells, and macrophages, and found that Treg cells shifted macrophages into M2-like type cells; in contrast, DEXs stimulated macrophages to express both M1 and M2-like type cells but with a greater tendency towards the M1-like type. Collectively, these results indicated that DEXs activated Treg cells, and that the activated Treg cells then regulated the polarization of macrophages and shifted macrophages into an M2-like type to protect cardiac function after MI. To address the low retention rates and short-lived therapeutic effects of DEXs, we used an alginate hydrogel to load DEXs. Previous studies showed that the Gel had good tolerance with a low incidence of adverse events [16], and that it could provide physical support and increase scar thickness in damaged myocardium when injected into the infarcted area after MI [17]. However, these is still controversy with regards to whether a single Gel injection could help improve cardiac function after MI [18–20]. Our results demonstrated that a single Gel injection increased the thickness of the infarcted wall but failed to improve cardiac function after MI. However, this strategy did protect cardiac function from exacerbating over time when compared with the MI group. Considering that the Gel provides physical support to the infarcted area after MI, the combined application of Gel with bioactive factors that have therapeutic effects could provide a much better approach. Previous research showed that the Gel could prolong the retention
of sEVs and improve cardiac function after MI [20]. How-
erver, prior to this study, it remained unknown whether
Gel could affect the migration of DEXs or enhance their
therapeutic effects with regards to protecting cardiac
function after MI. In the present study, we found that
DEXs-Gel prolonged the retention time of DEXs in vivo
and had no detrimental effects on the migration of DEXs.
We also found that Gel enhanced therapeutic effects with
regards to cardiac function after MI, thus indicating that
DEXs-Gel is a superior approach for delivering DEXs.

MI and subsequent adverse ventricular remodeling
are still a major health concern worldwide [1]. Over
recent decades, researchers have gradually realized
the important role of inflammatory reactions after MI.
Excessive inflammation leads to adverse ventricular
remodeling and become harmful with regards to the
recovery of cardiac function. Evidence from two recent
trials also showed that the anti-inflammatory effects of
colchicine reduce the risk of cardiovascular events in
patients with recent myocardial infarction [26, 27]. An
investigation of MI mice models also showed that stem
cell therapy can enhance heart function after MI, these
effects were not associated with the production of new
cardiomyocytes; rather, this enhancement occurred via
an acute sterile immune response characterized by mac-
rophages [28]. These results emphasized that the ap-
propriate application of anti-inflammatory therapy after
MI could be of benefit to patients with MI. However, not
all applications of anti-inflammatory drugs can attenu-
ate injury [30], thus emphasizing the complex nature of
inflammatory reactions after MI and indicating that an
effective therapy should not only reduce the length and
damage of the inflammatory response but also promote
the activation of reparative pathways. As a novel non-cell
therapy, EXs have been reported to play an important
role in myocardial healing and cardiac remodeling after
MI [31–33]. However, the majority of previous studies
focused on the role of EXs secreted by stem cells, car-
diomyocytes, or fibroblasts [32, 33]. In comparison, the
potential role of EXs from immune cells has not received
significant levels of attention even though they make a
significant contribution to the repair of myocardial injury
after MI [12, 34]. As EXs are secreted by DCs, our pre-
vious studies demonstrated that DEXs could improve
cardiac function by activating CD4\(^+\) T cells [12] and
promote angiogenesis by exosomal miR-494-3p [34].
DEXs and miR-494-3p are both potential targets for
non-cell therapies. Some recent studies have shown that
the use of hydrogel as a carrier for microRNA is a safe
and effective interventionald strategy to delay and reverse
pathological progression [35, 36]. However, we and some
other researchers [37], found that the inflammation fol-
lowing MI is associated with the apoptosis of myocytes,
angiogenesis and fibrosis. Considering the vital role of
inflammation after MI, we chose DEXs as our target for
investigation. Therapy involving EXs still faces a major
challenge with regards to a short half-life that imposes
a significant limitation on therapeutic effects [13, 14].
Thus, we combined DEXs with Gel and developed a
novel delivery system for DEXs that did not affect DEXs
migration and enhanced their therapeutic effects after
MI. DEXs-Gel is easy to produce and has no detrimental
effects when injected into the myocardium. This prod-
uct cannot only provide physical support to the infarcted
myocardium; it may also provide benefits with regards
to immunoregulation, anti-apoptosis, and angiogenesis.
DEXs-Gel overcomes the short-therapeutic effects of
therapy involving DEXs and provides a long-term favora-
ble consequence to MI by combining the two advantages
of Gel and DEXs with regards to the protection of cardiac
function after MI. Furthermore, we clarified the mecha-
nism responsible for the migration of DEXs into the
lymph nodes and the activation of Treg cells (a subset of
CD4\(^+\) T cells) after MI. We found that Treg cells regulate
the polarization of macrophages in post-MI hearts and
shifts macrophages towards M2-like type cells in order
to improve cardiac function.

However, we still need to investigate how DEXs acti-
vate Treg cells and how Treg cells regulate the polariza-
tion of macrophages. A recent study revealed that Treg
cells could stimulate macrophages producing IL-10 by
secreting IL-13 [23]. Considering the secretion of IL-10
is one of the characteristic features of M2-like type mac-
rophages [38], Treg cells may regulate macrophage polar-
ization via IL-13. However, whether DEXs simulate CD4
T cells to differentiate into Treg cells or activate Treg cells
in lymph nodes directly, still needs further investigation.
Moreover, our study of DEXs-Gel was carried out in a
mouse model. In our future research, we will utilize large
animal, such as the pig, to investigate the potential of this
technique for clinical translation.

Conclusion
In this study, we confirmed that DEXs-Gel prolonged
the retention time of DEXs and had no detrimental
effects on the migration of DEXs, therefore enhanc-
ing the therapeutic effects of DEXs with regards to
improving cardiac function after MI. Compared with
single Gel or DEXs injection, the injection of DEXs-
Gel had better consequences on immunoregulation,
anti-apoptosis, the promotion of angiogenesis, and also
increased the thickness of the infarcted wall. We also
investigated the mechanisms by which DEXs improved
cardiac function and found that DEXs activated Treg
cells which then regulated macrophage polarization
and shifted macrophages towards M2-like type cells.
Our study developed a novel strategy for delivering DEXs and provided new insight into the use of immunotherapy to treat MI.

Abbreviations
MI: Myocardial infarction; DCs: Dendritic cells; BMDCs: Bone marrow-derived dendritic cells; BMMCs: Bone marrow-derived macrophage cells; EXs: Exosomes; DEXs: Dendritic cell-derived exosomes; Gel: Alginate hydrogel; DEXs-Gel: DEXs incorporated with alginate hydrogel, Treg cells: Regulatory T cells; ECM: Extracellular matrix; MSC: Bone marrow mesenchymal stem cell; sEVs: MSC-derived exosomes; TEM: Transmission electron microscopy; NTA: Nanoparticle tracking analysis; SEM: Scanning electron microscopy.

Acknowledgements
The authors thank Dr. Lu Ying for providing help with flow cytometry analysis, and Dr. Zhao Zhonghua for facilitating immunohistochemistry. We also thank Dr. Wang Guangxue for his help with small animal echocardiography.

Authors’ contributions
YZ performed MI model induction and treatments, immunofluorescence staining and drafted the work. ZC performed cell experiments, DEXs isolation and labeling. YS combined the DEXs and Gel and determined the release ability of the DEXs-Gel QL and WG performed some of the cell experiments. XZ and KY performed fluorescence imaging. JY designed the research and performed statistical analysis. HL designed the research, performed data analysis, and drafted the manuscript. All authors read and approved the final manuscript.

Funding
The present study was supported by the National Natural Science Foundation of China (NSFC Grants 81770350, 81870200 and 81400263).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
This study was approved by the Institutional Review Board of Zhongshan Hospital of Fudan University and the Shanghai Institutes of Biological Sciences-CAS (Reference: A5894-01). Written informed consent was obtained from each participant prior to enrollment.

Consent for publication
All authors agree with the submission and publication of this paper.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Cardiology, QingPu Branch of Zhongshan Hospital, Fudan University, Shanghai 201700, People’s Republic of China. 2 Department of Cardiology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200092, People’s Republic of China. 3 Department of Cardiology, Shanghai East Hospital of Clinical Medical College, Nanjing Medical University, Nanjing 211166, People’s Republic of China. 4 Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai 200032, People’s Republic of China.

Received: 12 July 2021 Accepted: 27 August 2021
Published online: 08 September 2021

References
1. Reed GW, Rossi JE, Cannon CP. Acute myocardial infarction. Lancet. 2017;389(10065):197–210.
2. Nahrendorf M, Pittet MJ, Swirski FK. Monocytes: protagonists of infarct inflammation and repair after myocardial infarction. Circulation. 2010;121(22):2437–45.
3. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29–322.
4. Sahoo S, Losordo DW. Exosomes and cardiac repair after myocardial infarction. Circ Res. 2014;114(2):333–44.
5. Sánchez-Alonso S, Alcaraz-Serna A, Sánchez-Madrid F, Alfranca A. Extracellular vesicle-mediated immune regulation of tissue remodeling and angiogenesis after myocardial infarction. Front Immunol. 2018;9:2799.
6. Zhang Y, Wen W, Liu H. The role of immune cells in cardiac remodeling after myocardial infarction. J Cardiovasc Pharmacol. 2020;76(4):407–13.
7. Kalluri R, LeBlu V. The biology, function, and biomedical applications of exosomes. Science. 2020. https://doi.org/10.1126/science.aau6977.
8. Gallet R, Dawkus J, Valle J, Simosko E, de Couto G, Middleton R, et al. Exosomes secreted by cardiomyocyte-derived cells reduce scarring, attenuate adverse remodelling, and improve function in acute and chronic porcine myocardial infarction. Eur Heart J. 2017;38(3):201–11.
9. Gao W, Liu H, Yuan J, Wu C, Huang D, Ma Y, et al. Exosomes derived from mature dendritic cells increase endothelial inflammation and atherosclerosis via membrane TNF-a mediated NF-kB pathway. J Cell Mol Med. 2016;20(12):2318–27.
10. Hood J, The association of exosomes with lymph nodes. Semin Cell Dev Biol. 2017;67:29–38.
11. De Toro, J, Herschlik L, Wdner C, Mongini C. Emerging roles of exosomes in normal and pathological conditions: new insights for diagnosis and therapeutic applications. Front Immunol. 2015;6:203.
12. Liu H, Gao W, Yuan J, Wu C, Yao K, Zhang L, et al. Exosomes derived from dendritic cells improve cardiac function via activation of CD4(+)-T lymphocytes after myocardial infarction. J Mol Cell Cardiol. 2016;91:123–33.
13. Armstrong JPK, Stevens MM. Strategic design of extracellular vesicle drug delivery systems. Adv Drug Deliv Rev. 2018;130:12–6.
14. van der Meer R, Fens MH, Vader P, van Solinge WW, Eniola-Adefeso O, Schifferles RM. Extracellular vesicles as drug delivery systems: lessons from the Liposome field. J Control Release. 2014;195:72–85.
15. Smyth T, Kullberg M, Malik N, Smith-Jones P, Graner MW, Anchordoquy TJ. Biodistribution and delivery efficiency of unmodified tumor-derived exosomes. J Control Release. 2015;199:145–55.
16. Ruvinov E, Cohen S. Alginate biomaterial for the treatment of myocardial infarction: progress, translational strategies, and clinical outlook: from ocean algae to patient bedside. Adv Drug Deliv Rev. 2016;96:54–76.
17. Freeman I, Kedem A, Cohen S. The effect of sulfation of alginate hydrogels on the specific binding and controlled release of heparin-binding proteins. Biomaterials. 2008;29(22):3260–8.
18. Wu Y, Chang T, Chen W, Wang X, Li J, Chen Y, et al. Release of VEGF and BMP9 from injectable alginate based composite hydrogel for treatment of myocardial infarction. Bioact Mater. 2021;6(2):520–8.
19. Fan C, Shi J, Zhuang Y, Zhang L, Huang L, Yang W, et al. Myocardial-infarction-responsive smart hydrogels targeting matrix metalloproteinase for on-demand growth factor delivery. Adv Mater. 2019;31(40): e1902900.
20. Lv K, Li Q, Zhang L, Wang Y, Zhong Z, Zhao J, et al. Incorporation of small extracellular vesicles in sodium alginate hydrogel as a novel therapeutic strategy for myocardial infarction. Theranostics. 2019;9(24):7403–16.
21. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol. 2004;22:531–62.
22. Freeman I, Kedem A, Cohen S. The effect of sulfation of alginate hydrogels on the specific binding and controlled release of heparin-binding proteins. Biomaterials. 2008;29(22):3260–8.
23. Weirather J, Hofmann UD, Beyersdorf N, Ramos GC, Vogel B, Frey A, et al. Foxp3+ CD4+ T cells improve healing after myocardial infarction by modulating monocye/macrophage differentiation. Circ Res. 2014;115(1):55–67.
24. Proto JD, Doran AC, Gusavota G, Yurdagul A J, Sozen E, Subramanian M, et al. Regulatory T cells promote macrophage effectorcytosis during inflammation resolution. Immunity. 2018;49(4):666-77.e6.
25. Choo EH, Lee JH, Park EH, Park HE, Jung NC, Kim TH, et al. Infarcted myocardium-primed dendritic cells improve remodeling and cardiac function after myocardial infarction by modulating the regulatory T cell and macrophage polarization. Circulation. 2017;135(15):1446–57.
26. Plochkin M, Baibav SR, Rufaihah AJ, Nithya V, Wang J, Shachaf Y, et al. The effect of matrix stiffness of injectable hydrogels on the preservation of cardiac function after a heart attack. Biomaterials. 2014;35(5):1429–38.
26. Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497–505.
27. Nedorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383(19):1838–47.
28. Vagnozzi RJ, Maillet M, Sargent MA, Khalil H, Johansen AKZ, Schwaneckamp JA, et al. An acute immune response underlies the benefit of cardiac stem cell therapy. Nature. 2020;577(7790):405–9.
29. Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueredo JL, et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med. 2007;204(12):3037–47.
30. Timmers L, Sluijter JP, Verlaan CW, Steendijk P, Cramer MJ, Emons M, et al. Cyclooxygenase-2 inhibition increases mortality, enhances left ventricular remodeling, and impairs systolic function after myocardial infarction in the pig. Circulation. 2007;115(9):326–32.
31. Alexander M, Hu R, Runtsch MC, Kagele DA, Mosbruger TL, Tilmachova T, et al. Exosome-delivered microRNAs modulate the inflammatory response to endotoxin. Nat Commun. 2015;6:7321.
32. Khan M, Nickoloff E, Abramova T, Johnson J, Verma SK, Krishnamurthy P, et al. Embryonic stem cell-derived exosomes promote endogenous repair mechanisms and enhance cardiac function following myocardial infarction. Circ Res. 2015;117(1):S2–64.
33. Bang C, Batkai S, Dangwal S, Gupta SK, Foingquinos A, Holzmann A, et al. Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. J Clin Investig. 2014;124(5):2136–46.
34. Liu H, Zhang Y, Yuan J, Gao W, Zhong X, Yao K, et al. Dendritic cell-derived exosomal miR-494-3p promotes angiogenesis following myocardial infarction. Int J Mol Med. 2021;47(1):315–26.
35. Xu Y, Niu Y, Wu B, Cao X, Gong T, Zhang ZR, et al. Extended-release of therapeutic microRNA via a host-guest supramolecular hydrogel to locally alleviate renal interstitial fibrosis. Biomaterials. 2021;275:120902.
36. Tao SC, Huang JY, Gao Y, Li ZX, Wei ZY, Dawes H, et al. Small extracellular vesicles in combination with sleep-related circRNA3503: a targeted therapeutic agent with injectable thermosensitive hydrogel to prevent osteoarthritis. Bioactive materials. 2021;6(12):4455–69.
37. Kologrivova I, Shtatolkina M, Suslova T, Ryabov V. Cells of the immune system in cardiac remodeling: main players in resolution of inflammation and repair after myocardial infarction. Front Immunol. 2021;12:664457.
38. Orecchioni M, Ghosheh Y, Pramod AB, Ley K. Macrophage polarization: different gene signatures in M1(LPS+) vs. classically and M2(LPS-) vs. alternatively activated macrophages. Front Immunol. 2019;10:1084.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.